Madrid, Spain.
the loss of smell is not just one of the factors of diagnosis early in the covid-19, Is also a symptom of good prognosis of the disease, according to international research led by scientists from the Universidad Complutense and the Hospital Clínic San Carlos in Madrid.
Through a study conducted in numerous centers, with the largest sample used to date (5,868 hospitalized patients) the researchers corroborated that although its origin is still a mystery, the anosmia -loss of smell– can act as a factor in good prognosis of the disease.
LEA: Netherlands suspends use of AstraZeneca vaccine out of concern
“These results have many implications, from initial patient assessment to the ability to understand the pathophysiology. Possibly, the invasion of the nasal epithelium causes that an adequate immunity is activated avoiding the cytokine storms“, Explained Jesús Porta-Etessam, head of the Neurology Section of the Hospital Clínic San Carlos, professor at the Faculty of Medicine of the Complutense University of Madrid (UCM) and first author of the work.
Also: Florida can start vaccinating the general public starting in April
In addition to identifying anosmia as a factor in good prognosis, researchers have also determined that olfactory and gustatory dysfunctions are more common in women (12.41% versus 8.67%), in children under 65 and in patients with kidney, lung, heart, neurological or oncological pathologies.
classify patients
The results obtained on a the symptoms Earlier coronavirus can serve as a criterion when classifying or taking patients therapeutic decisions, According to the Complutense University of Madrid in a note released on Monday.
The conclusions of this study could be used to elaborate “Risk indices” complication, which according to Porta-Etessam would be very useful and interesting when observing, treating or assessing the discharge of patients.
In addition to the UCM and the Hospital Clínic San Carlos, the Madrid hospitals of La Paz, Infanta Sofia, Our Lady of America, Porta de Ferro and Getafe have taken part in the study; the university hospitals Clínic de Valladolid (northwest of Spain), Virgen de la Arraixaca (Murcia) -southeast- Álvaro Cunqueiro (Vigo) -northwest- and Burgos (north); the Institute of Cardiology and Cardiovascular Surgery of Havana (Cuba); the General Hospital of the North of Guayaquil IESS the Ceibos (Ecuador) or the Clinic San Carlo of Milan (Italy). EFE